(Germline) mutations in receptor tyrosine kinases: A prognostic marker in multiple myeloma?

PO-001 Targeted sequencing of relapsed/ refractory myeloma patients identifies an enrichment of mutations in MAPK and Cereblon pathways K.M. Kortum, E.K. Mai, N.H. Hanafiah, S. Barrio, L. Bruins, M. Merz, J. Xu, K. Pashayeva, Y.X. Zhu, C.X. Shi, P. Jedlowski, G. Ahmann, M. Andrulis, J. Hillengass, H. Goldschmidt, R. Fonseca, P.L. Bergsagel, E. Braggio, M.S. Raab, A.K. Stewart Department of Hematology, Mayo Clinic in Arizona, USA; Department of Internal Medicine V, Heidelberg University Hospital, Germany; Institute of Pathology, Heidelberg University Hospital, Germany; National Center of Tumor Diseases (NCT), Germany; German Cancer Research Center (DKFZ)